+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating treatments for patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer that is locally advanced or metastatic. This phase III, global, randomized, open-label study compares the effectiveness and safety of inavolisib combined with fulvestrant versus alpelisib combined with fulvestrant. Participants have experienced disease progression during or after therapy with cyclin dependent kinase 46 inhibitors combined with endocrine therapy. Participants receive study drugs in repeated 28-day cycles. Inavolisib is taken orally once daily at 9 mg on days 1 to 28 of each cycle, while fulvestrant is administered at 500 mg on days 1 and 15 of the first cycle and day 1 of subsequent cycles. The comparator group receives alpelisib at 300 mg orally once daily plus fulvestrant on the same schedule. A substudy evaluates the effect of inavolisib plus fulvestrant on the metabolism of certain enzyme substrates by administering midazolam, omeprazole, and bupropion on specified days within the first cycle. Participants undergo regular assessments including tumor evaluations per RECIST criteria, blood tests, and monitoring of drug levels. The primary outcome measures progression-free survival assessed by independent review up to approximately 64 months. Secondary outcomes include overall survival, response rates, quality of life, and safety events monitored up to about 85 months. The study includes frequent visits during treatment cycles and follow-ups to evaluate side effects and long-term outcomes.

Age: 18Years +All GendersPhase 3
210 locations
I

Actively Recruiting

This observational study focuses on patients with metastatic Urothelial Carcinoma UC who have been treated with specific therapies. It aims to retrospectively analyze patients who received pembrolizumab as first-line therapy if they were not suitable for platinum chemotherapy, or as second-line therapy after progression following platinum-based chemotherapy. The study also includes patients treated with enfortumab vedotin after progression following platinum chemotherapy and anti-PD-1PD-L1 inhibitors. These analyses help understand treatment outcomes in this patient group. The study examines patients who received at least one cycle of pembrolizumab between January 1, 2018, and November 30, 2021, or at least one cycle of enfortumab vedotin between June 1, 2022, and July 31, 2023. Both treatments are evaluated based on their prior use following platinum-based chemotherapy and progression status. The study does not involve new treatments but reviews patient records to assess outcomes related to these therapies. Participants clinical data will be reviewed to measure overall survival, progression-free survival, and overall response rate to pembrolizumab or enfortumab vedotin. Secondary analysis includes the impact of smoking habits, obesity, and other medications on treatment outcomes. The study involves no active intervention and lasts until September 30, 2027, with data collected retrospectively to better understand treatment effectiveness and patient prognostic factors.

Age: 18Years +All Genders
1 location
A

Actively Recruiting

This research aims to gather and analyze real-world data on treatments for patients with metastatic prostate cancer in three specific settings. It focuses on patients with metastatic hormonecastration-sensitive prostate cancer mCSPC treated with androgen deprivation therapy ADT plus androgen receptor signaling inhibitors ARSI or with ADT, ARSI, and docetaxel. It also includes patients with metastatic castration-resistant prostate cancer mCRPC treated with Lutetium-177 PSMA therapy or with PARP inhibitors either alone or combined with ARSI, aiming to understand treatment outcomes across these groups. The study involves observing patients treated with various combinations ADTARSI or ADTARSIdocetaxel for mCSPC Lutetium-177 PSMA therapy for mCRPC and PARP inhibitors such as olaparib, niraparib, or talazoparib alone or with ARSI for mCRPC. These treatments reflect routine clinical management rather than investigational interventions. The study collects data retrospectively from these three patient groups to assess their treatment experiences and outcomes. Participants medical records and treatment histories will be reviewed to evaluate outcomes like overall survival, progression-free survival, and overall response rates for each treatment group. The study also examines time to progression based on metastatic sites and explores how lifestyle and other medications might influence outcomes. This observational study spans from January 31, 2024, to May 31, 2024, focusing on real-world treatment effects without requiring additional interventions or visits from participants.

Age: 18Years +All Genders
1 location
E

Actively Recruiting

This research aims to enhance self-management skills for adults with Type 2 Diabetes Mellitus T2DM living in the Marche region of Italy. It evaluates a mobile health m-health solution personalized by diabetologists and integrated with electronic patient records, comparing its use to usual diabetes care. The main goal is to measure changes in glycated haemoglobin HbA1c levels over a 12-month period to assess the effectiveness of this digital support. Participants will be randomly assigned to either a treated group using the m-health solution or a control group receiving regular care. The m-health system includes mobile apps for tracking health data such as blood sugar, physical activity, and diet, sending alerts and motivational messages, allowing communication with healthcare professionals, and providing access to educational materials. Healthcare providers will monitor patient data through an integrated electronic platform. The treatment lasts 12 months with evaluations at baseline, 4, 8, and 12 months. During the study, participants will engage in clinical assessments and complete validated questionnaires covering disease severity, medication adherence, lifestyle habits, self-efficacy, and quality of life. Data will be collected from self-reports, clinical visits, and the m-health app. Researchers will also explore patients experience and satisfaction with the m-health solution and assess its cost-effectiveness. No extra visits or lab tests beyond routine care are required.

Age: 18Years +All GendersPhase Not Applicable
11 locations
O

Actively Recruiting

Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.

Age: 18Years +All Genders
216 locations
S

Actively Recruiting

This research aims to study the epidemiology of invasive bacterial diseases caused by Streptococcus pneumoniae pneumococcus, Neisseria meningitidis meningococcus, and Haemophilus influenzae hemophilus. These infections can cause severe illness and serious complications. The study focuses on monitoring these infections to guide public health efforts, evaluate vaccine impacts, and plan prevention and treatment strategies by identifying circulating strains and assessing vaccine failures. The study uses molecular diagnostic testing to identify these bacteria from blood samples, even when traditional culture methods may fail due to prior antibiotic use or sample handling issues. Pediatric and adult patients diagnosed with invasive bacterial diseases caused by these pathogens are included. This approach enables more accurate detection and characterization of the bacteria. Participants diagnosed with these invasive bacterial infections will have their samples analyzed using molecular methods. Researchers will monitor the incidence rates of these infections in children, the distribution of bacterial types, and the proportion of cases preventable by vaccination. The study will also assess vaccine failure rates. The average study duration for outcome measurement is about one year, supporting improved surveillance and public health interventions.

Age: 1Day - 70YearsAll Genders
38 locations
G

Actively Recruiting

Researchers are conducting a global registry to monitor the long-term safety and effectiveness of Increlex therapy in children and adolescents with Severe Primary Insulin-like Growth Factor-1 Deficiency SPIGFD. This observational, non-interventional registry collects data from multiple countries including Austria, France, Germany, Italy, Poland, Spain, Sweden, the United Kingdom, and the USA. The main goal is to gather safety information during treatment and for at least five years after treatment ends. The registry includes participants who are starting, planning to start, or already receiving Increlex treatment as per local prescribing information. Increlex mecasermin is given as an injection with doses ranging from 40 to 120 mcgkg twice daily, prescribed by a physician. Data may be collected retrospectively for those already on treatment. The study tracks participants over long periods to observe treatment exposure, dose, and various health outcomes related to growth and development. Participants will be monitored for adverse events, including serious events and neoplasia, during treatment and up to five years afterward. Researchers will also assess changes in height, bone age, body mass index, pubertal stage, and quality of life. Biological markers like growth hormone and IGF-1 levels will be measured periodically. The registry collects comprehensive data on safety, effectiveness, and other health indicators to better understand outcomes in children and adolescents receiving Increlex therapy.

Age: 2Years - 18YearsAll Genders
58 locations
I

Actively Recruiting

Researchers are conducting the ARON-1 Study, an international and multicenter observational study, to gather worldwide experiences on using immuno-combination therapies for patients with metastatic renal cell carcinoma RCC. This research includes two supplementary studies focused on analyzing genomic signatures from tumor samples and characterizing immune cell populations in patients treated with first-line immuno-combinations for advanced RCC. The treatments being evaluated include combinations such as pembrolizumab plus axitinib, nivolumab plus ipilimumab, nivolumab plus cabozantinib, pembrolizumab plus lenvatinib, avelumab plus axitinib, and atezolizumab plus bevacizumab. These therapies are studied as first-line treatments for metastatic RCC, allowing researchers to compare outcomes across different immuno-combination regimens. Participants provide data retrospectively, with researchers reviewing clinical outcomes such as progression-free survival, overall survival, and overall response rate. Additional analyses focus on treatment efficacy in elderly patients, patients with bone or brain metastases, and those with non-clear cell RCC. The study also examines the prognostic impact of smoking and obesity. Data collection continues until September 2027, with no direct intervention or active treatment administration during the study period.

Age: 18Years +All Genders
1 location
P

Actively Recruiting

Researchers are evaluating treatments for advanced breast cancer that is hormone receptor HR-positive and HER2-low or ultralow, classified as non-luminal subtype by gene expression profiling PAM50. This phase II international study compares trastuzumab deruxtecan T-DXd with a physicians choice of CDK46 inhibitor plus endocrine therapy ET to see which better prolongs progression-free survival in these patients. Participants will be randomly assigned to receive either T-DXd at 5.4 mgkg body weight by intravenous infusion every 21 days or one of several CDK46 inhibitors palbociclib, ribociclib, or abemaciclib combined with an endocrine therapy fulvestrant, letrozole, anastrozole, or exemestane chosen by their doctor. Treatment will continue in 21-day cycles, and the study will assess outcomes over up to 25 months. During the study, participants will undergo regular assessments including imaging scans to evaluate tumor response and progression. Researchers will monitor progression-free survival, overall survival, response rates, quality of life, and safety through adverse event tracking. Follow-up and treatment adherence will be closely observed to understand the effects and tolerability of these therapies in this specific breast cancer subtype.

Age: 18Years +All GendersPhase 2
79 locations
R

Actively Recruiting

Researchers are evaluating whether casdatifan combined with cabozantinib can improve progression-free survival compared to placebo plus cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma. The study focuses on patients who have previously received anti-PD-1 or anti-PD-L1 therapies in their most recent treatment, with no more than one prior metastatic treatment regimen. This is a randomized, double-blind, active-controlled phase 3 trial aimed at advancing treatment options for this patient group. Participants will be randomly assigned to receive either casdatifan and cabozantinib or placebo and cabozantinib, both taken orally. The study includes two treatment arms one experimental arm with casdatifan and cabozantinib, and a comparator arm with placebo and cabozantinib. Treatment is ongoing, with monitoring for up to approximately 33 months for key outcomes, and follow-up for overall survival up to about 64 months. Throughout the study, participants will undergo regular assessments including imaging scans evaluated by a blinded independent review to measure tumor response and progression. Researchers will track progression-free survival, overall survival, response rates, duration of response, disease control, and treatment-related adverse events. Symptom changes will also be monitored using patient-reported measures. The total participation duration may extend up to several years to capture long-term outcomes and safety data.

Age: 18Years +All GendersPhase 3
191 locations